HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer

Tao Jiang, Qiqi Jin, Jiahao Wang, Fengying Wu, Jian Chen, Gongyan Chen, Yunchao Huang, Ying Cheng, Qiming Wang, Yueyin Pan, Jianying Zhou, Jianhua Shi, Xingxiang Xu, LiZhu Lin, Wei Zhang, Yiping Zhang, Yunpeng Liu, Yong Fang, Jifeng Feng, Zhehai Wang, Sheng Hu, Jian Fang, Yongqian Shu, Jiuwei Cui, Yi Hu, Wenxiu Yao, Xingya Li, Xiaoyan Lin, Rui Wang, Yongsheng Wang, Wei Shi, Gaohua Feng, Jun Ni, Beibei Mao, Dandan Ren, Huaibo Sun, Henghui Zhang, Luonan Chen, Caicun Zhou, Shengxiang RenClinical 2023 · DOI

Abstract

These findings suggest that high HED could portend survival benefit in advanced NSCLC treated with first-line PD-1 blockade plus chemotherapy. See related commentary by Dimou, p. 4706.
BibTeX
@inproceedings{jiang2023hla,
  author = {Tao Jiang and Qiqi Jin and Jiahao Wang and Fengying Wu and Jian Chen and Gongyan Chen and Yunchao Huang and J. Chen and Ying Cheng and Qiming Wang and Yueyin Pan and Jianying Zhou and Jianhua Shi and Xingxiang Xu and LiZhu Lin and Wei Zhang and Yiping Zhang and Yunpeng Liu and Yong Fang and Jifeng Feng and Zhehai Wang and Sheng Hu and Jian Fang and Yongqian Shu and Jiuwei Cui and Yi Hu and Wenxiu Yao and Xingya Li and Xiaoyan Lin and Rui Wang and Yongsheng Wang and Wei Shi and Gaohua Feng and Jun Ni and Beibei Mao and Dandan Ren and Huaibo Sun and Henghui Zhang and Luonan Chen and Caicun Zhou and Shengxiang Ren},
  title = {{HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer}},
  booktitle = {Clinical},
  year = {2023},
  doi = {10.1158/1078-0432.ccr-23-0604},
}

Loading related content...

Figure